Piper Sandler analyst David Westenberg lowered the firm’s price target on NeoGenomics to $18 from $19 and keeps an Overweight rating on the shares. The analyst updated his model to reflect the recent earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NEO: